Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Leukocytes01:27

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

EML4-ALK mediates resistance to KRAS G12C inhibition and induces an oncogenic dependency by rewiring signaling through the wild-type RAS pathway.

Cancer discovery·2026
Same author

Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial.

Lancet (London, England)·2026
Same author

Biophysical and aerodynamic properties of a peptide targeting the A-kinase anchoring function of PI3Kγ for pulmonary cAMP modulation.

Scientific reports·2026
Same author

Epstein-Barr virus orchestrates spatial reorganization and immunomodulation in the classic Hodgkin lymphoma tumor microenvironment.

Cell reports. Medicine·2026
Same author

Targeting PI3Kγ anchoring enhances CFTR membrane localization and modulator efficacy via PKD1.

JCI insight·2026
Same author

Author Correction: Wiskott-Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma.

Nature medicine·2026
Same journal

Vascular RhoJ Is an Effective and Selective Target for Tumor Angiogenesis and Vascular Disruption.

Cancer cell·2026
Same journal

Intratumoral B cells under stress.

Cancer cell·2026
Same journal

Chronic stress unleashes an intratumor phage-fibroblast-B cell circuit to promote tumor growth.

Cancer cell·2026
Same journal

Molecular phenotypes and spatial archetypes: A new framework for cancer-associated fibroblasts.

Cancer cell·2026
Same journal

OpenIO: An open framework for AI-native immunotherapy.

Cancer cell·2026
Same journal

From prediction to interpretation in computational pathology.

Cancer cell·2026
See all related articles

Related Experiment Video

Updated: May 23, 2026

Identification of Quiescent Cells in a Zebrafish T-Cell Acute Lymphoblastic Leukemia Model Using Cell Proliferation Staining
06:41

Identification of Quiescent Cells in a Zebrafish T-Cell Acute Lymphoblastic Leukemia Model Using Cell Proliferation Staining

Published on: July 19, 2024

Calming down T cell acute leukemia.

Emilio Hirsch1, Roberto Chiarle

  • 1Molecular Biotechnology Center, University of Torino, Torino, Italy. emilio.hirsch@unito.it

Cancer Cell
|April 21, 2012
PubMed
Summary
This summary is machine-generated.

Signaling from phosphoinositide 3-kinase (PI3K) is frequently altered in blood cancers. This study reveals that inhibiting PI3K gamma and delta isoforms can effectively treat T-cell acute lymphoblastic leukemia (T-ALL).

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Related Experiment Videos

Last Updated: May 23, 2026

Identification of Quiescent Cells in a Zebrafish T-Cell Acute Lymphoblastic Leukemia Model Using Cell Proliferation Staining
06:41

Identification of Quiescent Cells in a Zebrafish T-Cell Acute Lymphoblastic Leukemia Model Using Cell Proliferation Staining

Published on: July 19, 2024

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Deregulation of class I phosphoinositide 3-kinase (PI3K) signaling is common in leukemia and lymphoma.
  • The specific PI3K isoforms implicated in T-cell acute lymphoblastic leukemia (T-ALL) have remained unidentified.

Discussion:

  • This study identifies PI3K gamma (γ) and PI3K delta (δ) isoforms as key players in T-ALL pathogenesis.
  • Targeting these specific PI3K isoforms offers a potential therapeutic strategy for T-ALL.

Key Insights:

  • Subramaniam et al. demonstrate that inhibiting PI3K γ and δ isoforms is effective in treating T-ALL.
  • This finding opens new avenues for targeted therapies in T-cell malignancies.

Outlook:

  • Further research into PI3K isoform-specific inhibitors could lead to novel treatments for T-ALL.
  • Understanding PI3K pathway dysregulation is crucial for developing precision medicine approaches in hematologic cancers.